<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The alpha-glucosidase inhibitor <z:chebi fb="0" ids="2376">acarbose</z:chebi> has been used for more than 20 years in the management of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Owing to its unique mode of action in the gastrointestinal tract, its properties are very different from other <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> medications </plain></SENT>
<SENT sid="2" pm="."><plain>Patients on long-term treatment to control a <z:hpo ids='HP_0011010'>chronic</z:hpo> disease are not only interested in good treatment efficacy, but are also even more interested in the safety and side effects of their medications </plain></SENT>
<SENT sid="3" pm="."><plain>Significant aspects of <z:chebi fb="0" ids="2376">acarbose</z:chebi> predominantly regarding safety and tolerability in the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> are reviewed </plain></SENT>
<SENT sid="4" pm="."><plain>It is concluded that <z:chebi fb="0" ids="2376">acarbose</z:chebi> is a convenient long-term treatment option, with benefits for both type 2 diabetics and patients in a <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic state</z:e> </plain></SENT>
</text></document>